SIM
WHWK

Spark Investment Management’s Whitehawk Therapeutics WHWK Stock Holding History

Spark Investment Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-687
Closed -$31K – 828
2018
Q3 		$31K Buy
+687
New +$38.6K ﹤0.01% 647

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Spark Investment Management's WHWK Position: Q4 2018 in Review

Spark Investment Management sold out of Whitehawk Therapeutics (WHWK) in Q4 2018, closing a stake of 687 shares — an estimated $31K sold.

Spark Investment Management first reported a position in WHWK in Q3 2018 and held it in 1 quarter. The position peaked at $31K in Q3 2018. 24 funds tracked by Wall St. Rank hold WHWK as of Q4 2018.

  • Spark Investment Management reported no remaining Whitehawk Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Spark Investment Management sold 687 Whitehawk Therapeutics shares in Q4 2018, an estimated $31K.
  • Spark Investment Management first reported a position in Whitehawk Therapeutics in Q3 2018 and held it in 1 quarter.
  • Spark Investment Management's Whitehawk Therapeutics position peaked at $31K in Q3 2018.
  • 24 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2018.

Based on Spark Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.